Senseonics Holdings

Senseonics Holdings, Inc. engages in the design, development, and commercialization of an implantable continuous glucose monitoring system for people with diabetes. Its primary product is the brand Eversense, a glucose monitoring device which includes sensors, smart transmitters, and mobile applications. The company was founded on June 26, 2014 and is headquartered in Germantown, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Senseonics achieves FDA milestone with Eversense 365, focuses on growth

Senseonics had a pivotal quarter with FDA approval of Eversense 365, driving positive feedback and strong adoption.
Financially, the company reported Q3 net revenue of $4.3 million with a gross loss of $4.1 million, focusing on cost reduction.
Efforts to reduce operating expenses and extend cash runway aim to address financial challenges and enhance stability.
With opportunities to accelerate sales, improve diabetes management, and expand market reach, Senseonics is poised for growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Senseonics Holdings, Inc. is a medical technology company, which engages in the development and manufacture of glucose monitoring products. Its primary product is the brand Eversense CGM (continuous glucose monitoring) including sensors, smart transmitters, and mobile applications. The company was founded on June 26, 2014 and is headquartered in Germantown, MD.

GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its second quarter 2023 financial results after market close on Thursday, August 10, 2023. Management will hold a conference call to review the Company's second quarter 2023 performance starting at 4:30 p.

Senseonics Holdings, Inc. Schedules Second Quarter 2023 Earnings Release and Conference Call for August 10, 2023 at 4:30 p.m. Eastern Time

Bionano Genomics

Brenmiller Energy Ltd

Faraday Future Intelligent Electric

Soluna Holdings, Inc.

T2 Biosystems

Today's penny stock market is brimming with high-volatility stocks. That especially relates to those that fall into the category of the cheapest penny stocks.

Best Penny Stocks To Buy Now? 6 Under $1 To Watch Now

Some of the most volatile penny stocks today are the cheapest. This idea of “cheap” is in the sense that prices are extremely low compared to other stocks.

3 Penny Stocks Under $1 To Watch Before August 2023

Applied Blockchain Inc

VAALCO Energy

Investing in penny stocks can be a good strategy to diversify your portfolio. These small-cap companies provide opportunities to be exposed to exponential gains due to their volatility and fast growth.

3 Penny Stocks to Buy to Turn $5,000 into $1 Million

Hycroft Mining Holding Corporation

Investing in the stock market is no child's play; it can sometimes seem like a rollercoaster ride. While some investors prefer to play it safe with large, blue-chip stocks, others seek the thrill of the high-risk, high-reward realm of penny stocks.

3 Top Penny Stocks to Watch Under $1 This Week

GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it had made equity grants to new employees under its 2019 Inducement Plan (the “Plan”) in accordance with NYSE American Company Guide Section 711(a). On July 3, 2023, Senseonics Compensation Committee granted 4 new non-execut.

Senseonics Announces Equity Grants To Employees Under Inducement Plan

GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today highlighted new clinical data presented at the American Diabetes Association 83rd Scientific Session. Two studies were presented demonstrating the safety and accuracy of the Eversense E3 CGM system. “These data further bolster Eversense's p.

New Clinical Data Demonstrating the Safety and Accuracy of Eversense through 365 Days Presented at the American Diabetes Association 83rd Scientific Sessions

TuSimple Holdings

Terawulf

If you're looking to buy penny stocks right now, you've got your work cut out for you. The massive volatility in the stock market today is unlike what many have seen in recent years.

3 Penny Stocks to Buy For Under $4 But Are They Worth The Risk?

Shares of medical technology company Senseonics Holdings Inc. SENS, -0.52% gained 6.7% premarket on Friday after the company announced that UnitedHealth Group Inc.'s UNH, +1.31% UnitedHealthcare, a major health insurer, would provide coverage of its implantable continuous glucose monitoring system. The coverage of the Eversense E3 CGM System will start July 1 for people with type 1 and insulin-requiring type 2 diabetes, Senseonics said in a release.

Senseonics shares jump 6.7% on new insurance coverage for continuous glucose monitor

GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that UnitedHealthcare, the largest health insurance company in the United States, will begin providing coverage for the Eversense E3 CGM System effective July 1, 2023 for people with type 1 and insulin-requiring type 2 diabetes. ".

Senseonics Announces UnitedHealthcare Coverage of Eversense® E3 CGM for Adults with Diabetes

GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in the upcoming Jefferies Healthcare Conference in New York, NY. Management is scheduled to present on Friday, June 9, 2023, from 9:30am to 9:55am ET. Interested parties may access a live and recorded webcast.

Senseonics to Participate in the Jefferies Healthcare Conference

Senseonics Holdings (SENS) came out with a quarterly loss of $0.03 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.03 per share a year ago.

Senseonics Holdings (SENS) Reports Q1 Loss, Tops Revenue Estimates

Senseonics Holdings, Inc. (NYSE:SENS ) Q2 2023 Earnings Conference Call May 9, 2023 4:30 PM ET Company Participants Philip Taylor - IR Tim Goodnow - President and CEO Rick Sullivan - CFO Mukul Jain - COO Conference Call Participants Sam Eiber - BTIG Colin Clark - Stifel Operator Good day, and welcome to the Senseonics First Quarter 2023 Earnings Conference Call. All participants will be in listen-only mode.

Senseonics Holdings, Inc. (SENS) Q1 2023 Earnings Call Transcript

GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today reported financial results for the quarter ended March 31, 2023. Recent Highlights & Accomplishments: Generated revenue of $4.1 million in the first quarter of 2023. Ascensia Diabetes Care, Senseonics' global commercial partner, is expa.

Senseonics Holdings, Inc. Reports First Quarter 2023 Financial Results

PARSIPPANY, N.J. , May 9, 2023 /PRNewswire/ -- Ascensia Diabetes Care, a global diabetes care company, maker of the CONTOUR® Blood Glucose Monitoring (BGM) System portfolio and exclusive distributor of Eversense® Continuous Glucose Monitoring (CGM) Systems, announces that it has significantly expanded Eversense PASS, a Payment Assistance and Simple Savings program designed to enhance affordability and access to the Eversense E3 CGM System.

ASCENSIA DIABETES CARE EXPANDS PAYMENT ASSISTANCE AND SIMPLE SAVINGS PROGRAM FOR EVERSENSE E3 CGM SYSTEM

Aditxt Inc

Clover Health Investments

Novo Integrated Sciences, Inc.

OPKO Health

Spectrum Pharma

Tuya

Penny stocks to buy for under $1 but are they worth the risk? The post 7 Hot Penny Stocks Under $1.10 To Watch This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

7 Hot Penny Stocks Under $1.10 To Watch This Week

GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its first quarter 2023 financial results after market close on Tuesday, May 9, 2023. Management will hold a conference call to review the Company's first quarter 2023 performance starting at 4:30 p.m. (East.

Senseonics Holdings, Inc. Schedules First Quarter 2023 Earnings Release and Conference Call for May 9, 2023, at 4:30 p.m. Eastern Time

Novocure

Veeva Systems

In discussing healthcare tech stocks, it pays to understand what healthcare technology is broadly. Healthcare technology, also known as HealthTech, refers to any technology developed to improve the healthcare system.

The 3 Most Promising Healthcare Tech Stocks for April 2023

PARSIPPANY, N.J., April 24, 2023 /PRNewswire/ -- Ascensia Diabetes Care, a global diabetes care company, maker of the CONTOUR® Blood Glucose Monitoring (BGM) system portfolio and exclusive distributor of Eversense® Continuous Glucose Monitoring (CGM) Systems, marks the one-year anniversary of launching Eversense® E3 in the U.S. with a commercial update and outlook on future innovation, as discussed in the recent Eversense CGM Virtual Analyst and Investor Event.

ASCENSIA DIABETES CARE MARKS ONE-YEAR ANNIVERSARY OF US EVERSENSE E3 CGM LAUNCH WITH COMMERCIAL UPDATE AND INNOVATION OUTLOOK

Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced the first pediatric study participant has been inserted with Eversense® 365-day system as part of the pivotal ENHANCE clinical trial at the AMCR Institute, a clinical research center focused on pre-diabetes, type 1, type 2 diabetes and obesity, under the direction of Dr. Timothy Bailey.

Senseonics Announces the First Pediatric Study Participant Insertions in the ENHANCE Clinical Trial

Enovis Corp

Esperion Therapeutics

Edgewise Therapeutics

SELLAS Life Sciences Group

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Top 5 Health Care Stocks That Preparing To Pump This Quarter - Enovis (NYSE:ENOV), Esperion Therapeutics (NASDAQ:ESPR)

GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today reported financial results for the quarter and full year ended December 31, 2022. Recent Highlights & Accomplishments: Generated fourth quarter 2022 revenue of $5.6 million and full year 2022 revenue of $16.4 million.

Senseonics Holdings, Inc. Reports Fourth Quarter and Full Year 2022 Financial Results

GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to host a joint virtual analyst and investor event alongside PHC Holdings Corporation, the parent company of Senseonics' global commercial partner, Ascensia Diabetes Care, on Wednesday, March 15, 2023 at 6:30pm ET.

Senseonics Holdings, Inc. and PHC Holdings Corporation To Host Joint Eversense CGM Virtual Analyst and Investor Event on March 15, 2023

Solo Brands

Guardion Health Sciences Inc

Hall of Fame Resort & Entertainment

Microvast Holdings

Seanergy Maritime Hlds

XWELL Inc

This article focuses on penny stocks with “buy” ratings from analysts. Analysts have access to information about  companies that retail investors cannot obtain.

7 Penny Stocks That Actually Have Buy Ratings

Senseonics to Present at the Stifel 2022 Healthcare Conference

News for Senseonics Holdings Stock (SENS)